Literature DB >> 31147303

Ocular Manifestations of Cutis Marmorata Telangiectatica Congenita.

Vaidehi S Dedania1, Omar Moinuddin2, Lisa M Lagrou3, Sanjana Sathrasala2, Flavio Mac Cord Medina4, Monte A Del Monte2, Emmanuel Y Chang5, Brenda L Bohnsack2, Cagri G Besirli6.   

Abstract

PURPOSE: To describe the range of ocular manifestations in cutis marmorata telangectatica congenita (CMTC).
DESIGN: Multicenter, retrospective, nonconsecutive case series. PARTICIPANTS: Patients with a diagnosis of CMTC referred for ophthalmologic evaluation between January 1, 2015, and December 31, 2018.
METHODS: Evaluation of ocular findings at presentation, systemic manifestations suggestive of a diagnosis of CMTC, genetic testing, and visual outcomes after treatment. MAIN OUTCOME MEASURES: Visual acuity, findings on ophthalmoscopy, and results of fluorescein angiography.
RESULTS: Nine patients with CMTC diagnosed clinically based on stereotypical cutaneous vascular malformations were included. The median age at presentation was 8 weeks (range, 2 weeks-4 years). Six patients were female and 3 were male. Avascular retina was identified on dilated fundus examination, fluorescein angiography, or both in 11 eyes of 6 patients. Retinal neovascularization was present bilaterally in 2 patients at presentation. One patient demonstrated retinal venous tortuosity, and another patient showed mild straightening of nasal retinal vessels in both eyes. Two patients (2 eyes) demonstrated retinal detachment (RD). Both were managed surgically. One infant demonstrated RD, whereas the other child showed extensive neovascularization and later progressed to combined tractional-rhegmatogenous detachment. A unique constellation of lacy peripheral capillary anomalies with prominent terminal vascular bulbs was noted in 3 patients. Granular pigment abnormalities were noted in the macula in 5 patients. Two patients demonstrated glaucoma, 1 requiring surgical intervention. Two patients demonstrated features of Adams-Oliver syndrome, with genetic testing identifying a Notch1 mutation in 1 patient.
CONCLUSIONS: Retinal vascular abnormalities in CMTC may occur more frequently than recognized previously. Given the variability of ocular involvement and the potential for rapidly progressive retinal vascular abnormalities and development of RD, complete ophthalmologic evaluation including measurement of intraocular pressure, gonioscopy, dilated fundus examination, and fluorescein angiography is recommended in infants with suspected CMTC shortly after birth. The distinct pattern of lacy capillary anomalies with prominent terminal bulbs seen in CMTC has not been described in other syndromes of vascular dysgenesis. Therefore, ophthalmic examination may be a valuable method to distinguish CMTC from other disorders demonstrating similar dermatologic and systemic manifestations.
Copyright © 2019 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31147303     DOI: 10.1016/j.oret.2019.03.025

Source DB:  PubMed          Journal:  Ophthalmol Retina        ISSN: 2468-6530


  4 in total

1.  Atypical Adams-Oliver syndrome with typical ocular signs of familial exudative vitreoretinopathy.

Authors:  En-Zhong Jin; Lyu-Zhen Huang; Ming-Wei Zhao; Hong Yin
Journal:  Int J Ophthalmol       Date:  2022-08-18       Impact factor: 1.645

2.  Adams Oliver syndrome: A mimicker of familial exudative vitreoretinopathy.

Authors:  Alwaleed M Alsulaiman; Hamad M Alsulaiman; Ahmad Almousa; Sulaiman M Alsulaiman
Journal:  Am J Ophthalmol Case Rep       Date:  2020-04-22

3.  Two AOS genes attributed to familial exudative vitreoretinopathy with microcephaly: Two case reports.

Authors:  Zhiyan Tao; Shaochong Bu; Fang Lu
Journal:  Medicine (Baltimore)       Date:  2021-03-05       Impact factor: 1.817

Review 4.  A Primer on a Comprehensive Genetic Approach to Vascular Anomalies.

Authors:  Alexandra J Borst; Taizo A Nakano; Francine Blei; Denise M Adams; Jessica Duis
Journal:  Front Pediatr       Date:  2020-10-19       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.